S&P 500 7,565.97 -0.58% NASDAQ 26,873.76 -0.81% DOW 50,835.13 -0.92% R2K 2,901.29 -1.05% VIX 16.11 +2.16%
Next Bullish Trade
VRTX Vertex Pharmaceuticals Incorporated NMS
$426.25 +1.16 (+0.27%)
Pullback · -0.91σ
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $3.0B $1.0B $1.1B $1.3B 34.5% 38.1%
2025-12-31 $3.2B $1.2B $1.1B $0.3B 37.3% 35.4%
2025-09-30 $3.1B $1.1B $1.2B $1.1B 35.2% 40.3%
2025-06-30 $3.0B $1.0B $1.2B $0.9B 34.8% 38.9%
2025-03-31 $2.8B $0.6B $1.0B $0.8B 23.3% 37.2%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-05-04 4.47 4.31 +3.8%
2026-02-12 4.65 4.58 +1.4%
2025-11-03 4.80 4.58 +4.9%
2025-08-04 3.99 3.72 +7.3%
2025-05-05 2.49 3.76 -33.7%
2025-02-10 3.98 4.02 -1.0%
2024-11-04 4.38 4.13 +6.0%
2024-08-01 -12.83 -11.75 -9.2%
2024-05-06 4.76 4.06 +17.3%
2024-02-05 4.20 4.09 +2.8%
2023-11-06 4.08 3.97 +2.7%
2023-08-01 3.89 3.88 +0.1%
2023-05-01 3.05 3.00 +1.6%
2023-02-07 3.76 3.51 +7.0%
2022-10-27 4.01 3.64 +10.1%
2022-08-04 3.60 3.50 +2.8%
2022-05-05 3.52 3.54 -0.4%
2022-01-26 3.37 3.29 +2.5%
2021-11-02 3.56 3.07 +15.8%
2021-07-29 3.11 2.38 +30.7%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
VRTX ★ $108B 25.3 19.9 8.9 20.6 5.6 54.4% 7.8% 61.4% 2.57%
LLY $969B 38.5 24.4 13.4 27.3 31.1 82.8% 55.5% 169.9% 0.95%
UNH $349B 28.9 18.4 0.8 18.5 3.6 18.8% 2.0% 0.7% 5.07%
JNJ $540B 26.0 17.6 5.6 16.6 6.7 68.0% 9.9% -52.9% 2.32%
MRK $286B 32.6 12.1 4.4 11.2 6.2 76.7% 4.9% — 4.91%
ABBV $387B 106.8 13.5 6.2 14.8 -58.1 72.0% 12.4% -46.2% 5.38%
PFE $145B 19.4 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.53%
TMO $175B 26.0 17.3 3.9 19.4 3.3 40.9% 6.2% 11.3% 3.15%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 49.71%

HolderShares% out
Capital World Investors 25,368,124 10.00%
Blackrock Inc. 23,969,517 9.44%
Capital Research Global Investors 21,125,964 8.32%
Vanguard Capital Management LLC 16,512,810 6.51%
State Street Corporation 11,730,139 4.62%
JPMORGAN CHASE & CO 7,033,156 2.77%
Geode Capital Management, LLC 6,139,621 2.42%
Vanguard Portfolio Management LLC 5,145,609 2.03%
Capital International Investors 5,126,077 2.02%
LOOMIS SAYLES & CO L P 4,003,821 1.58%

Insider activity · 90d

No insider trades for VRTX in last 90d.

Analyst estimates

yfinance
Low
$330.0
Mean
$548.68964
High
$641.0
Analysts
29

Consensus: buy (mean 1.60606). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
4 2026-06-02 FORM 4 view ·
4 2026-05-19 FORM 4 view ·
4 2026-05-19 FORM 4 view ·
4 2026-05-14 FORM 4 view ·
8-K 2026-05-13 8-K view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
4 2026-05-05 FORM 4 view ·
10-Q 2026-05-05 10-Q view ·
8-K 2026-05-04 8-K view ·
8-K 2026-04-29 8-K view ·
4 2026-04-17 FORM 4 view ·
4 2026-04-17 FORM 4 view ·
4 2026-04-17 FORM 4 view ·
4 2026-04-03 FORM 4 view ·
DEF 14A 2026-04-02 DEF 14A view ·
4 2026-03-31 FORM 4 view ·
8-K 2026-03-31 8-K view ·
4 2026-03-17 FORM 4 view ·
4 2026-03-13 FORM 4 view ·
4 2026-03-06 FORM 4 view ·
4 2026-03-04 FORM 4 view ·
4 2026-03-03 FORM 4 view ·
4 2026-03-03 FORM 4 view ·
4 2026-03-02 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-26 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·
4 2026-02-18 FORM 4 view ·

About

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule…